Cite
Are N-methyl-D-aspartate receptor antagonists or acetylcholinesterase inhibitors more effective in slowing cognitive decline in Parkinson's disease dementia?
MLA
Gretchen Shelesky, et al. “Are N-Methyl-D-Aspartate Receptor Antagonists or Acetylcholinesterase Inhibitors More Effective in Slowing Cognitive Decline in Parkinson’s Disease Dementia?” Evidence-Based Practice, vol. 21, June 2018, pp. E7–8. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....790162aedcfb5517de52a4260a81b884&authtype=sso&custid=ns315887.
APA
Gretchen Shelesky, Maria Felton, Megan Carr, & Vincent Balestrino. (2018). Are N-methyl-D-aspartate receptor antagonists or acetylcholinesterase inhibitors more effective in slowing cognitive decline in Parkinson’s disease dementia? Evidence-Based Practice, 21, E7–E8.
Chicago
Gretchen Shelesky, Maria Felton, Megan Carr, and Vincent Balestrino. 2018. “Are N-Methyl-D-Aspartate Receptor Antagonists or Acetylcholinesterase Inhibitors More Effective in Slowing Cognitive Decline in Parkinson’s Disease Dementia?” Evidence-Based Practice 21 (June): E7–8. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....790162aedcfb5517de52a4260a81b884&authtype=sso&custid=ns315887.